Targeting New Pathways in Alopecia Areata: The Role of JAK Inhibitors

Target Audience
This educational activity has been designed to meet the needs of dermatologists, pediatricians, primary care clinicians, and others involved in the management of patients with AA.

Program Overview
While rare, affecting 1-2% of the population, alopecia areata (AA) presents numerous psychophysical consequences that impact patient quality of life. Currently, there are no approved treatments for AA and management options are limited. However, new therapies are on the horizon that have the potential to change the treatment landscape.

Watch as our esteemed clinician faculty discuss the emerging Janus kinase (JAK) therapies for AA. Complemented with case-based learning and testimonial from a patient ambassador, this activity is designed to improve outcomes for patients with AA

Learning Objectives
Upon completion of this activity, participants should be better able to:

Discuss the epidemiology of AA and the impact of this disease on patient quality of life
Understand the clinical manifestations of AA to improve evaluation of disease severity
Employ strategies to individualize treatment for patients with AA
Summarize the pathophysiology of AA
Discuss emerging therapies for AA, including JAK inhibitors, JAK/TEC inhibitors, and clinical trial data